Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News


openaccessgovernment.org > research-priorities-for-jrmds-from-disease-control-to-living-well > 213597

Research priorities for jRMDs: From disease control to living well

1+ week, 8+ hour ago   (458+ words) Advances in immunology and targeted therapies have transformed outcomes for many young people. However, research must now look beyond controlling inflammation alone. The wider objective should be to identify disease earlier, personalise treatment and enable young people to participate fully…...


healio.com > news > dermatology > 20/26/0901 > taltz-zepbound-combo-yields-sustained-improvement-at-1-year-in-psoriatic-disease-obesity

Taltz, Zepbound combo yields sustained improvement at 1 year in psoriatic disease, obesity

1+ week, 5+ day ago   (54+ words) Adults with moderate to severe psoriatic disease and overweight or obesity saw sustained or continued improvement in disease activity at 1 year with tirzepatide plus ixekizumab vs. ixekizumab monotherapy, according to a Lilly press release.One-year data from the phase 3b, randomized,…...